R
Ravindre Panchia
Researcher at University of the Witwatersrand
Publications - 48
Citations - 3177
Ravindre Panchia is an academic researcher from University of the Witwatersrand. The author has contributed to research in topics: Viral load & HPTN 052. The author has an hindex of 17, co-authored 46 publications receiving 2553 citations. Previous affiliations of Ravindre Panchia include Chris Hani Baragwanath Hospital & University of North Carolina at Chapel Hill.
Papers
More filters
Journal ArticleDOI
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
Myron S. Cohen,Ying Q. Chen,Marybeth McCauley,Theresa Gamble,Mina C. Hosseinipour,Nagalingeswaran Kumarasamy,James Hakim,Johnstone Kumwenda,Beatriz Grinsztejn,José Henrique Pilotto,Sheela Godbole,Suwat Chariyalertsak,Breno Santos,Kenneth H. Mayer,Irving F. Hoffman,Susan H. Eshleman,Estelle Piwowar-Manning,Leslie Cottle,Xinyi C. Zhang,Joseph Makhema,Lisa A. Mills,Ravindre Panchia,Sharlaa Faesen,Joseph J. Eron,Joel E. Gallant,Diane V. Havlir,Susan Swindells,Vanessa Elharrar,David N. Burns,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Max Essex,Sarah E. Hudelson,Andrew D. Redd,Thomas R. Fleming +35 more
TL;DR: The early initiation of ART led to a sustained decrease in genetically linked HIV-1 infections in sexual partners, and was associated with a 93% lower risk of linked partner infection than was delayed ART.
Journal ArticleDOI
Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial
Beatriz Grinsztejn,Mina C. Hosseinipour,Heather J. Ribaudo,Susan Swindells,Joseph J. Eron,Ying Q. Chen,Lei Wang,San San Ou,Maija Anderson,Marybeth McCauley,Theresa Gamble,N. Kumarasamy,James Hakim,Johnstone Kumwenda,José Henrique Pilotto,Sheela Godbole,Suwat Chariyalertsak,Marineide Gonçalves de Melo,Kenneth H. Mayer,Susan H. Eshleman,Estelle Piwowar-Manning,Joseph Makhema,Lisa A. Mills,Ravindre Panchia,Ian Sanne,Joel E. Gallant,Irving F. Hoffman,Taha E. Taha,Karin Nielsen-Saines,David D. Celentano,Max Essex,Diane V. Havlir,Myron S. Cohen +32 more
TL;DR: The clinical benefits recorded, combined with the striking reduction in HIV-1 transmission risk previously reported, provides strong support for earlier initiation of antiretroviral treatment.
Journal ArticleDOI
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial
Ian Sanne,Catherine Orrell,Matthew P. Fox,Francesca Conradie,Prudence Ive,Jennifer Zeinecker,Morna Cornell,Christie Heiberg,Charlotte Ingram,Ravindre Panchia,Mohammed Rassool,René Gonin,Wendy S. Stevens,Handre Truter,Marjorie Dehlinger,Charles van der Horst,James McIntyre,Robin Wood +17 more
TL;DR: In this paper, the authors compared outcomes of nurse versus doctor management of ART care for HIV-infected patients, and found that nurse-monitored ART is non-inferior to doctor-controlled ART.
Journal ArticleDOI
Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial
Mark F. Cotton,Avy Violari,Kennedy Otwombe,Ravindre Panchia,Els Dobbels,Helena Rabie,Deirdre Josipovic,Afaaf Liberty,Erica Lazarus,Steve Innes,Anita Janse van Rensburg,Wilma Pelser,Handre Truter,Shabir A. Madhi,Edward Handelsman,Patrick Jean-Philippe,James McIntyre,Diana M. Gibb,Abdel Babiker +18 more
TL;DR: Early time-limited ART had better clinical and immunological outcomes than deferred ART, with no evidence of excess disease progression during subsequent treatment interruption and less overall ART exposure than deferredART.
Journal ArticleDOI
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
Raphael J. Landovitz,Sue Li,Beatriz Grinsztejn,Halima Dawood,Albert Y. Liu,Manya Magnus,Mina C. Hosseinipour,Ravindre Panchia,Leslie Cottle,Gordon Chau,Paul G. Richardson,Mark A. Marzinke,Craig W. Hendrix,Susan H. Eshleman,Yinfeng Zhang,Elizabeth E. Tolley,Jeremy Sugarman,Ryan Kofron,Adeola Adeyeye,David N. Burns,Alex R. Rinehart,David Margolis,William Spreen,Myron S. Cohen,Marybeth McCauley,Joseph J. Eron +25 more
TL;DR: In this study, CAB LA was well tolerated at the doses and dosing intervals used and was not detectable in plasma both at the time of first reactive HIV test and at the study visit 12 weeks prior to the first reactive test.